Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
61.60
+0.67 (+1.10%)
Streaming Delayed Price
Updated: 10:23 AM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutic
< Previous
1
2
3
4
5
6
7
Next >
Halozyme Therapeutics Shares Jump On Better Than Expected Annual Guidance
August 10, 2022
Via
Benzinga
Halozyme Therapeutics: Q2 Earnings Insights
August 09, 2022
Halozyme Therapeutics (NASDAQ:HALO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 02, 2022
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Biotech Stocks With Key Catalysts Coming in July
June 27, 2022
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.
Via
InvestorPlace
Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact
March 24, 2022
Halozyme Therapeutics Inc (NASDAQ: HALO) has
Via
Benzinga
Earnings Scheduled For February 22, 2022
February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu...
Via
Benzinga
Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International
May 24, 2022
Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.
Via
Benzinga
MindMed Appoints Schond L. Greenway As CFO
May 23, 2022
Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.
Via
Benzinga
Recap: Halozyme Therapeutics Q1 Earnings
May 10, 2022
Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Halozyme Therapeutics's Earnings Outlook
May 09, 2022
Halozyme Therapeutics (NASDAQ:HALO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Why Is Sierra Oncology (SRRA) Stock Up Today?
April 13, 2022
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.
Via
InvestorPlace
Why Antares Pharma Stock Is Soaring Today
April 13, 2022
Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing...
Via
Benzinga
Why Is Antares Pharma (ATRS) Stock Up Today?
April 13, 2022
Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO).
Via
InvestorPlace
Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More
April 13, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
April 13, 2022
GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.
Via
Investor's Business Daily
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13
April 13, 2022
Reuters Blackrock To Introduce Its First China ETF In 2022: Reuters According to two people with close knowledge of the matter, BlackRock, Inc. (NYSE: BLK) plans to launch...
Via
Benzinga
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
April 13, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
April 13, 2022
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties
April 08, 2022
Via
Benzinga
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
March 22, 2022
Argenx SE (NASDAQ: ARGX) ) has
Via
Benzinga
Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth
February 23, 2022
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million....
Via
Benzinga
Halozyme Therapeutics: Q4 Earnings Insights
February 22, 2022
Halozyme Therapeutics (NASDAQ:HALO) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 10, 2021
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 23.65% to $2.81 during Friday's regular session. As of 12:30 EST, BioLine Rx's stock is trading at a...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
December 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...
Via
Benzinga
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
December 07, 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.
Via
InvestorPlace
Exposures
COVID-19
Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma
December 02, 2021
Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with...
Via
Benzinga
Exposures
Product Safety
Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook
November 03, 2021
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of $101.94 million....
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.